A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on
quality of life of two different doses of belimumab administered in addition to standard
therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE)
disease.